4 Breast Cancer Stocks to Watch During Breast Cancer Awareness MonthZacks Investment Research · Oct 16, 2026
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Oct 2, 2026
Olema Pharmaceuticals, Inc. (OLMA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha · Sep 15, 2026
Olema Pharmaceuticals, Inc. (OLMA) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeeking Alpha · Sep 10, 2026
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Sep 2, 2026
Olema Oncology to Participate in Upcoming Investor ConferencesGlobeNewsWire · Aug 31, 2026Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 10, 2026 | -$0.55 | -$0.61 | Miss |
| May 12, 2026 | -$0.52 | -$0.52 | Beat |
| Mar 16, 2026 | -$0.51 | -$0.50 | Beat |
| Nov 10, 2025 | -$0.44 | -$0.49 | Miss |
| Aug 11, 2025 | -$0.43 | -$0.51 | Miss |
| May 13, 2025 | -$0.49 | -$0.36 | Beat |